These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. New developments in biomarkers for melanoma. Griewank KG; Ugurel S; Schadendorf D; Paschen A Curr Opin Oncol; 2013 Mar; 25(2):145-51. PubMed ID: 23334230 [TBL] [Abstract][Full Text] [Related]
9. Old and new serological biomarkers in melanoma: where we are in 2009. Mouawad R; Spano JP; Khayat D Melanoma Res; 2010 Apr; 20(2):67-76. PubMed ID: 20093989 [TBL] [Abstract][Full Text] [Related]
10. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561 [TBL] [Abstract][Full Text] [Related]
11. Update of diagnostic and prognostic markers in cutaneous malignant melanoma. Reed JA; Albino AP Clin Lab Med; 2000 Dec; 20(4):817-38. PubMed ID: 11221516 [TBL] [Abstract][Full Text] [Related]
12. [Immuno-diagnosis of malignant melanoma]. Szekeres G; Battyáni Z Magy Onkol; 2003; 47(1):45-50. PubMed ID: 12704454 [TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094 [TBL] [Abstract][Full Text] [Related]
14. Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients. Campillo JA; Martínez-Escribano JA; Moya-Quiles MR; Marín LA; Muro M; Guerra N; Parrado A; Campos M; Frías JF; Minguela A; García-Alonso AM; Alvarez-López MR Clin Cancer Res; 2006 Aug; 12(16):4822-31. PubMed ID: 16914567 [TBL] [Abstract][Full Text] [Related]
15. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993 [TBL] [Abstract][Full Text] [Related]
16. Common skin cancers. Lee PK Minn Med; 2004 Mar; 87(3):44-7. PubMed ID: 15080294 [TBL] [Abstract][Full Text] [Related]
17. Factors associated with melanoma incidence and prognosis. Lee JE Semin Surg Oncol; 1996; 12(6):379-85. PubMed ID: 8914201 [TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Ladányi A Pigment Cell Melanoma Res; 2015 Sep; 28(5):490-500. PubMed ID: 25818762 [TBL] [Abstract][Full Text] [Related]
19. [Laboratory markers of melanoma progression]. Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]